Enzo Biochem's Q3 Revenues Rise 22 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday that its third-quarter revenues increased 22 percent, due in part to the firm's acquisitions of Biomol and Assay Designs over the past year.

The New York-based firm said that revenues for its Enzo Life Sciences segment increased 44 percent to $12.4 million from $8.6 million year over year. Products revenues for that segment jumped 50 percent to $10.5 million, due largely to the addition of revenues from Biomol and Assay Designs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.